Skip to main content
Premium Trial:

Request an Annual Quote

Xerion Pharmaceuticals Acquires Rights to Tufts Cancer Targets

NEW YORK, Feb. 26 – Xerion Pharmaceuticals has acquired exclusive rights to cancer targets identified by a Tufts University scientist, the company said today.

The Martinsried, Germany-based firm, in a statement, said it will use the targets to create therapeutic antibodies. The targets were identified in the lab of Daniel Jay, a professor of physiology at Tufts.

Financial details of the agreement were not disclosed.

Xerion was founded in 1998 by former MorphoSys employees and is based on a technology developed by Jay. 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.